Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

被引:58
|
作者
Lapitz, Ainhoa [1 ,2 ]
Azkargorta, Mikel [3 ,4 ]
Milkiewicz, Piotr [5 ,6 ]
Olaizola, Paula [1 ,2 ,4 ]
Zhuravleva, Ekaterina [7 ]
Grimsrud, Marit M. [8 ,9 ]
Schramm, Christoph [10 ,11 ,12 ]
Arbelaiz, Ander [1 ,2 ]
O'Rourke, Colm J. [7 ]
La Casta, Adelaida [1 ,2 ]
Milkiewicz, Malgorzata [13 ]
Pastor, Tania [1 ,2 ]
Vesterhus, Mette [8 ,14 ]
Jimenez-Aguero, Raul [1 ,2 ]
Dill, Michael T. [15 ,16 ]
Lamarca, Angela [17 ]
Valle, Juan W. [17 ]
Macias, Rocio I. R. [18 ]
Izquierdo-Sanchez, Laura [1 ,2 ,4 ]
Castano, Ylenia Perez [1 ,2 ,19 ]
Caballero-Camino, Francisco Javier [1 ,2 ]
Riano, Ioana [1 ,2 ,20 ]
Krawczyk, Marcin [21 ]
Ibarra, Cesar [22 ]
Bustamante, Javier [22 ]
Nova-Camacho, Luiz M. [23 ]
Falcon-Perez, Juan M. [4 ,24 ,25 ]
Elortza, Felix [3 ,4 ]
Perugorria, Maria J. [1 ,2 ,4 ,26 ]
Andersen, Jesper B. [7 ]
Bujanda, Luis [1 ,2 ,4 ,26 ]
Karlsen, Tom H. [8 ]
Folseraas, Trine [8 ,27 ]
Rodrigues, Pedro M. [1 ,2 ,4 ,25 ]
Banales, Jesus M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ,17 ,18 ,19 ,20 ,21 ,22 ,23 ,24 ,25 ,26 ,27 ,28 ]
机构
[1] Donostia Univ Hosp, Biodonostia Hlth Res Inst, Dept Liver & Gastrointestinal Dis, Paseo Dr Begiristain S-N, E-20014 San Sebastian, Spain
[2] Univ Basque Country UPV EHU, Donostia Univ Hosp, Biodonostia Hlth Res Inst, Dept Liver & Gastrointestinal Dis, San Sebastian, Spain
[3] Prote Platform, CIC bioGUNE, Basque Res & Technol Alliance BRTA, ProteoRed ISCIII, Derio, Spain
[4] ISCIII, Natl Inst Study Liver & Gastrointestinal Dis CIBE, Madrid, Spain
[5] Med Univ Warsaw, Dept Gen Transplant & Liver Surg, Liver & Internal Med Unit, Warsaw, Poland
[6] Pomeranian Med Univ, Translat Med Grp, Szczecin, Poland
[7] Univ Copenhagen, Dept Hlth & Med Sci, Biotech Res & Innovat Ctr, Copenhagen, Denmark
[8] Oslo Univ Hosp, Div Surg Inflammatory Med & Transplantat, Dept Transplantat Med, Norwegian PSC Res Ctr,Rikshosp, Oslo, Norway
[9] Univ Oslo, Inst Clin Med, Oslo, Norway
[10] European Reference Network Hepatol Dis ERN RARE L, Hamburg, Germany
[11] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 1, Hamburg, Germany
[12] Univ Med Ctr Hamburg Eppendorf, Martin Zeitz Ctr Rare Dis, Hamburg, Germany
[13] Pomeranian Med Univ, Dept Med Biol, Szczecin, Poland
[14] Univ Bergen, Dept Clin Sci, Bergen, Norway
[15] Univ Heidelberg Hosp, Dept Gastroenterol Infect Dis & Intoxicat, Heidelberg, Germany
[16] German Canc Res Ctr, Expt Hepatol Inflammat & Canc, Heidelberg, Germany
[17] Univ Manchester, Dept Med Oncol, Christie NHS Fdn Trust, Div Canc Sci, Manchester, Lancs, England
[18] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, Expt Hepatol & Drug Targeting HEVEPHARM, Salamanca, Spain
[19] Bidasoa Hosp, Dept Digest Syst, Osakidetza Basque Hlth Serv, Bidasoa IHO, Irun, Spain
[20] Biodonostia Hlth Res Inst, Clin Res Unit, Spanish Clin Res Network SCReN ISCIII, San Sebastian, Spain
[21] Saarland Univ, Saarland Univ Med Ctr, Dept Med 2, Homburg, Germany
[22] Cruces Univ Hosp, Osakidetza Basque Hlth Serv, Ezkerraldea Enkarterri Cruces IHO, Baracaldo, Spain
[23] Donostia Univ Hosp, Dept Pathol, Osakidetza Basque Hlth Serv, Donostialdea IHO, San Sebastian, Spain
[24] BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Exosomes Lab, Derio, Spain
[25] Basque Fdn Sci, Ikerbasque, Bilbao, Spain
[26] Univ Basque Country, Fac Med & Nursing, Dept Med, UPV EHU, Leioa, Spain
[27] Oslo Univ Hosp, Gastroenterol Sect, Dept Transplantat Med, Oslo, Norway
[28] Univ Navarra, Sch Sci, Dept Biochem & Genet, Pamplona, Spain
关键词
Cholangiocarcinoma; Primary sclerosing cholangitis; Protein biomarkers; Extracellular vesicles; Liquid biopsy; Mass spectrometry; Single-cell RNA-sequencing; PRIMARY SCLEROSING CHOLANGITIS; EXTRACELLULAR VESICLES;
D O I
10.1016/j.jhep.2023.02.027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Cholangiocarcinoma (CCA), heterogeneous biliary tumours with dismal prognosis, lacks accurate early diagnostic methods especially important for individuals at high-risk (i.e. those with primary sclerosing cholangitis [PSC]). Here, we searched for protein biomarkers in serum extracellular vesicles (EVs).Methods: EVs from patients with isolated PSC (n = 45), concomitant PSC-CCA (n = 44), PSC who developed CCA during follow-up (PSC to CCA; n = 25), CCAs from non-PSC aetiology (n = 56), and hepatocellular carcinoma (n = 34) and healthy individuals (n = 56) were characterised by mass spectrometry. Diagnostic biomarkers for PSC-CCA, non-PSC CCA, or CCAs regardless of aetiology (Pan-CCAs) were defined and validated by ELISA. Their expression was evaluated in CCA tumours at a single-cell level. Prognostic EV biomarkers for CCA were investigated.Results: High-throughput proteomics of EVs identified diagnostic biomarkers for PSC-CCA, non-PSC CCA, or Pan-CCA, and for the differential diagnosis of intrahepatic CCA and hepatocellular carcinoma, which were cross-validated by ELISA using total serum. Machine learning-based algorithms disclosed CRP/FIBRINOGEN/FRIL for the diagnosis of PSC-CCA (local disease [LD]) vs. isolated PSC (AUC = 0.947; odds ratio [OR] =36.9) and, combined with carbohydrate antigen 19-9, overpowers carbohydrate antigen 19-9 alone. CRP/PIGR/VWF allowed the diagnosis of LD non-PSC CCAs vs. healthy individuals (AUC = 0.992; OR = 387.5). It is noteworthy that CRP/FRIL accurately diagnosed LD Pan-CCA (AUC = 0.941; OR = 89.4). Levels of CRP/FIBRINOGEN/ FRIL/PIGR showed predictive capacity for CCA development in PSC before clinical evidence of malignancy. Multi-organ tran-scriptomic analysis revealed that serum EV biomarkers were mostly expressed in hepatobiliary tissues, and single-cell RNA sequencing and immunofluorescence analysis of CCA tumours showed their presence mainly in malignant cholangiocytes. Multivariable analysis unveiled EV prognostic biomarkers, with COMP/GNAI2/CFAI and ACTN1/MYCT1/PF4V associated nega-tively and positively with patients' survival, respectively.Conclusions: Serum EVs contain protein biomarkers for the prediction, early diagnosis, and prognostication of CCA that are detectable using total serum, representing a tumour cell-derived liquid biopsy tool for personalised medicine.& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:93 / 108
页数:17
相关论文
共 50 条
  • [1] Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells
    Lapitz, Ainhoa
    Azkargorta, Mikel
    Milkiewicz, Piotr
    Olaizola, Paula
    Zhuravleva, Ekaterina
    Grimsrud, Marit M.
    Schramm, Christoph
    Arbelaiz, Ander
    Rourke, Colm O.
    La Casta, Adelaida
    Milkiewicz, Malgorzata
    Pastor, Tania
    Vesterhus, Mette
    Jimenez-Aguero, Raul
    Dill, Michael
    Lamarca, Angela
    Valle, Juan
    Macias, Rocio I. R.
    Izquierdo-Sanchez, Laura
    Castano, Ylenia Perez
    Caballero, Francisco J.
    Riano, Ioana
    Krawczyk, Marcin
    Ibarra, Cesar
    Bustamante, Javier
    Nova-Camacho, Luiz Miguel
    Falcon-Perez, Juan
    Elortza, Felix
    Perugorria, Maria Jesus
    Andersen, Jesper
    Bujanda, Luis
    Karlsen, Tom Hemming
    Folseraas, Trine
    Miguel Rodrigues, Pedro
    Maria Banales, Jesus
    [J]. JOURNAL OF HEPATOLOGY, 2023, 78 : S541 - S542
  • [2] Discovery of liquid biopsy-based novel protein biomarkers for early detection of breast cancer metastasis
    Jinno, Cynthia
    Tanaka, Sunao
    Fujii, Takeo
    Furuya, Hideki
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [3] Advances in cancer early diagnosis with liquid biopsy-based approaches
    Zhang, Wei
    [J]. JOURNAL OF CANCER METASTASIS AND TREATMENT, 2021, 7
  • [4] Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
    Kilgour, Elaine
    Rothwell, Dominic G.
    Brady, Ged
    Dive, Caroline
    [J]. CANCER CELL, 2020, 37 (04) : 485 - 495
  • [5] Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis
    Pang, Bairen
    Zhu, Ying
    Ni, Jie
    Thompson, James
    Malouf, David
    Bucci, Joseph
    Graham, Peter
    Li, Yong
    [J]. THERANOSTICS, 2020, 10 (05): : 2309 - 2326
  • [6] Centrifugation affects the purity of liquid biopsy-based tumor biomarkers
    Rikkert, Linda G.
    van der Pol, Edwin
    van Leeuwen, Ton G.
    Nieuwland, Rienk
    Coumans, Frank A. W.
    [J]. CYTOMETRY PART A, 2018, 93A (12) : 1207 - 1212
  • [7] Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer
    Wenjie Shi
    Thomas Wartmann
    Sara Accuffi
    Sara Al-Madhi
    Aristotelis Perrakis
    Christoph Kahlert
    Alexander Link
    Marino Venerito
    Verena Keitel-Anselmino
    Christiane Bruns
    Roland S. Croner
    Yue Zhao
    Ulf D. Kahlert
    [J]. British Journal of Cancer, 2024, 130 : 125 - 134
  • [8] Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer
    Shi, Wenjie
    Wartmann, Thomas
    Accuffi, Sara
    Al-Madhi, Sara
    Perrakis, Aristotelis
    Kahlert, Christoph
    Link, Alexander
    Venerito, Marino
    Keitel-Anselmino, Verena
    Bruns, Christiane
    Croner, Roland S.
    Zhao, Yue
    Kahlert, Ulf D.
    [J]. BRITISH JOURNAL OF CANCER, 2023, 130 (01) : 43 - 52
  • [9] Advances in oral cancer early diagnosis and treatment strategies with liquid biopsy-based approaches
    Balachander, Kannan
    Priyadharsini, Jayaseelan Vijayashree
    Paramasivam, Arumugam
    [J]. ORAL ONCOLOGY, 2022, 134
  • [10] Liquid biopsy-based microRNA models as potential biomarkers of bowel conditions
    Rapado-Gonzalez, Oscar
    Lopez-Lopez, Rafael
    Suarez-Cunqueiro, Marfa Mercedes
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2023, 115 (02) : 59 - 63